Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.51 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.51 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.36 |
| ▸ | TGFBR1 | P36897 | 12/20 | 0.33 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.33 |
| ▸ | SMAD2 | Q15796 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14621521 | 0.81 | JAK2 (0.40) | TGFBR1KDM4ENPC1RAB9AHKDC1 | |
| SCHEMBL4548306 | 0.80 | TGFBR1 (0.32) | ADORA2AADORA2BLRRK2TGFBR1KDM4E | |
| SCHEMBL16867222 | 0.71 | ADORA2A (0.67) | ADORA2AADORA2BTGFBR1MAPK1DYRK1A | |
| SCHEMBL14297421 | 0.69 | ADORA2A (0.59) | ADORA2AADORA2BLRRK2KDM4ERAB9A | |
| SCHEMBL4296143 | 0.69 | ALDH1A1 (0.52) | KDM4ENPC1RAB9AHKDC1TDP1 | |
| SCHEMBL12438877 | 0.68 | MAPT (0.46) | TGFBR1BMPR1ASMAD2KDM4ENPC1 | |
| SCHEMBL4048510 | 0.68 | GAA (0.45) | LRRK2TGFBR1BMPR1ASMAD2MAPK1 | |
| SCHEMBL30093444 | 0.68 | GAA (0.45) | LRRK2TGFBR1BMPR1ASMAD2MAPK1 | |
| SCHEMBL4560336 | 0.66 | ALDH1A1 (0.50) | KDM4ENPC1RAB9AHKDC1TDP1 | |
| SCHEMBL10258516 | 0.66 | ADORA2A (0.50) | ADORA2AADORA2BALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8168649-B2 | Niacin receptor agonists, compositions containing such compounds and methods of treatment | Merk Sharp & Dohme Corp. (US) | 2012-05-01 | — | — | US | disclosed |
| US-20100144778-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME LLC | 2010-06-10 | — | — | US | disclosed |
| US-20090170891-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME CORP. | 2009-07-02 | — | — | US | disclosed |
| US-20090062269-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME CORP. | 2009-03-05 | — | — | US | disclosed |
| US-20090042926-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME CORP. | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062269-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | HCAR1, HCAR2, FFAR1 | ADORA2A 23/4885ADORA2B 129/4885LRRK2 3670/4885 |
| US-20090170891-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | HCAR1, HCAR2, FFAR1 | ADORA2A 23/4885ADORA2B 129/4885LRRK2 3670/4885 |
| US-20100144778-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | HCAR1, HCAR2, GPR119 | ADORA2A 27/4885ADORA2B 128/4885LRRK2 3690/4885 |
| US-20090042926-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | HCAR1, HCAR2, GPR119 | ADORA2A 27/4885ADORA2B 128/4885LRRK2 3690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.